As our data indicates an association between TNF-α and colon cancer migration capacity it would be reasonable to evaluate a drug such as Infliximab (monoclonal anti TNF-α antibody) which has no association with postoperative adverse side effects [25]. This evidence concerns the gene TNF and colonic neoplasm.